News

Nymox Reports 2014 Financial Results

March 31, 2015:

March 31, 2015: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today its financial results for the year ended December 31, 2014 prepared in accordance with International Financial Reporting Standards.


Nymox Announces Private Placements of US $400,000

March 19, 2015:

March 19, 2015: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today recent private placements of 883,058 shares, with total proceeds of US$400,000.


Nymox Announces $1.07 Million Financing

December 18, 2014:

December 18, 2014: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today the closing of U.S. $1.07 million in financing, consisting of a 3 year term convertible debenture at 6% with conversion at $0.53.


Nymox Reports Third Quarter 2014 Financial Results

November 14, 2014:

November 14, 2014: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today its financial results for the third quarter of 2014


Nymox NX-1207 BPH Pivotal Phase 3 U.S. Studies NX02-0017 and NX02-0018 Fail to Meet Primary Efficacy Endpoints

November 2, 2014:

November 2, 2014: Nymox announced today that the Company’s two Phase 3 U.S. studies of NX-1207 for the treatment of BPH, NX02-0017 and NX02-0018, failed to meet their primary efficacy endpoints.


Nymox Announces Positive Prostate Cancer 8 Month Clinical Trial Results

September 10, 2014:

September 10, 2014: Nymox announced today new positive outcome results from the Company’s ongoing prospective NX03-0040 trial of NX-1207 for the treatment of low grade localized prostate cancer.


Nymox Reports Positive Update on Nerve Sparing and Sexual Function Preservation in Men Treated With NX-1207

June 17, 2014:

June 17, 2014: Nymox is pleased to announce new data supporting the positive sexual functional preservation profile of NX-1207, the Company’s lead compound in Phase 3 development for the treatment of prostate enlargement (BPH or benign prostatic hyperplasia)and Phase 2 development for localized prostate cancer.


Nymox Reports Positive New Safety Study Data For Phase 3 BPH Drug

June 11, 2014:

June 11, 2014: Nymox is pleased to announce new clinical data supporting the positive safety profile of NX-1207, the Company’s lead compound in late Phase 3 testing for prostate enlargement (BPH or benign prostate hyperplasia). Recent pharmacokinetic studies using a newly developed highly sensitive blood test for NX-1207 have shown that the drug is undetectable in the blood post-injection, providing strong evidence that the drug, once injected into the prostate, remains confined to the prostate and thus unable to affect other organs such as the liver, kidneys, heart, or testes.


Nymox Reports New Results on Favorable Side Effect Profile of NX-1207 Treatment

May 21, 2014:

May 21, 2014: Nymox is pleased to report new positive data confirming the advantageous side effect profile of the Company’s lead compound NX-1207. Results from the Brief Male Sexual Function Questionnaire (BMSF) in the Company’s recently completed NX03-0040 trial of NX-1207 2.5 mg and 15 mg for the treatment of low grade localized prostate cancer indicate that targeted treatment with NX-1207 at either dose had no significant effect on reported sexual function score post-treatment.


Nymox Reports Positive Results Showing That NX-1207 Treatment for Prostate Cancer Does Not Affect Testosterone Levels

May 13, 2014:

May 13, 2014: Nymox reported today positive new study findings showing that the Company’s NX-1207 Phase 2 treatment for localized low-risk prostate cancer did not affect testosterone levels in treated men.